Jefferies Global Healthcare Conference
Logotype for Hemab Therapeutics Holdings Inc

Hemab Therapeutics (COAG) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Hemab Therapeutics Holdings Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Sutacimig in Glanzmann thrombasthenia

  • Phase III single-arm design selected after constructive regulatory dialogue to control variability; trial targets 90% power to detect a minimum 50% effect.

  • Annualized treated bleed rate is the primary endpoint; regulators endorsed endpoints, dose and analysis plan, supported by a validated electronic bleed diary.

  • ~75 patients to enroll across multiple countries and sites; U.S. and two non-U.S. regions are open, with enrollment and timing metrics planned for H1 2027.

  • Phase II low-dose weekly results showed a 50% reduction in the intention-to-treat analysis and ~80% per-protocol; the pivotal design is powered for a minimum 50% effect.

  • Trial aims for broad eligibility among an estimated 800-1,000 U.S. patients; HEMLIBRA is a pricing reference, with ~$800,000 list cost and ~$650,000 average after weight adjustments.

Factor VII deficiency and broader potential

  • First clinical data showed up to a five-fold increase in total Factor VII and >50% reduction in prothrombin time; mutation-informed analysis may help predict responders.

  • Initial U.K. site results support adding countries and sites; more data are needed to finalize dose and regimen, with potential to leverage Glanzmann safety data.

  • The estimated 5,000 Factor VII patients reflect the severe population; moderate patients could expand reach if treatment is safe and effective.

  • Potential future sutacimig indications include Bernard-Soulier syndrome, other platelet disorders and treatment-resistant hemophilia A and B.

HMB-002 for von Willebrand disease

  • Data from 13 patients across 20, 50 and 150 mg cohorts showed dose proportionality and ~2.5-fold increases in von Willebrand factor and Factor VIII, normalizing average levels in the studied population.

  • February EAHAD update planned with a 300 mg single-ascending-dose cohort and initial 150 mg monthly multiple-dose data; 8-10 additional patients are expected to bring total data to over 20 patients.

  • Phase II is assessing prospectively collected annualized treated bleeds; at least 50% reduction is a preliminary efficacy benchmark, with minimum four-month baseline and up to four months of treatment follow-up.

  • 2027 is the expected timeframe to understand requirements for transition; management expects phase I/II could lead directly to a single pivotal trial.

  • Monovalent antibody targets residual endogenous von Willebrand factor; initial focus is type 1 and 2A, representing an estimated 90%-95% of patients, with data planned for February.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Hemab Therapeutics